0001140361-24-008273.txt : 20240216 0001140361-24-008273.hdr.sgml : 20240216 20240216073018 ACCESSION NUMBER: 0001140361-24-008273 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240212 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eterna Therapeutics Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 24645785 BUSINESS ADDRESS: STREET 1: 1035 CAMBRIDGE STREET STREET 2: SUITE 18A CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 10531 4S COMMONS DRIVE STREET 2: SUITE 166-550 CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. DATE OF NAME CHANGE: 20210325 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 8-K 1 ef20021627_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2024

Eterna Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
 001-11460
 31-1103425
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1035 Cambridge Street, Suite 18A
    
Cambridge, MA
  
02141
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (212) 582-1199

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading symbol
  
Name of each exchange on which registered
Common Stock, par value $0.005 per share
   ERNA
   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Mr. Peter Cicala to the Board. Mr. Cicala will serve as a member of the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected or appointed and qualified or his earlier death, resignation or removal. The Board determined that Mr. Cicala is as an “independent director” under applicable rules of the Nasdaq Stock Market. The Board also appointed Mr. Cicala to serve on each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.

There are no arrangements or understandings between Mr. Cicala and any other person pursuant to which Mr. Cicala was appointed as a member of the Board.

The Company has not engaged in any transaction, and there is no currently proposed transaction, in which Mr. Cicala had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.

Mr. Cicala will participate in the standard non-employee director compensation arrangements with respect to annual Board member compensation and Board committee member retainers described under the heading “Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with Securities and Exchange Commission on May 5, 2023. The Company also expects to enter into its standard director and officer indemnification agreement with Mr. Cicala.

-2-
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
Eterna Therapeutics Inc.
   
Dated: February 16, 2024
By:
 /s/ Sanjeev Luther
   
Sanjeev Luther
   
President and Chief Executive Officer


-3-
 EX-101.SCH 2 erna-20240212.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 erna-20240212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 4 erna-20240212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 12, 2024
Entity File Number 001-11460
Entity Registrant Name Eterna Therapeutics Inc.
Entity Central Index Key 0000748592
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 31-1103425
Entity Address, Address Line One 1035 Cambridge Street
Entity Address, Address Line Two Suite 18A
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 212
Local Phone Number 582-1199
Title of 12(b) Security Common Stock, par value $0.005 per share
Trading Symbol ERNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://eternatx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20021627_8k.htm erna-20240212.xsd erna-20240212_lab.xml erna-20240212_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20021627_8k.htm": { "nsprefix": "erna", "nsuri": "http://eternatx.com/20240212", "dts": { "inline": { "local": [ "ef20021627_8k.htm" ] }, "schema": { "local": [ "erna-20240212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "erna-20240212_lab.xml" ] }, "presentationLink": { "local": [ "erna-20240212_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://eternatx.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240212to20240212", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20021627_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240212to20240212", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20021627_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-24-008273-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-008273-xbrl.zip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end XML 16 ef20021627_8k_htm.xml IDEA: XBRL DOCUMENT 0000748592 2024-02-12 2024-02-12 false 0000748592 NASDAQ 8-K 2024-02-12 Eterna Therapeutics Inc. DE 001-11460 31-1103425 1035 Cambridge Street Suite 18A Cambridge MA 02141 212 582-1199 false false false false Common Stock, par value $0.005 per share ERNA false